^
    4ms
    A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells. (PubMed, Cell Oncol (Dordr))
    Overall, the engineering of a single-vector targeting IL10R CAR, which subsequently secretes CD33-targeted bsAb, addresses the issue of immune escape due to the heterogeneous expression of IL10R and CD33, and represents a promising progress in AML therapy aimed at improving treatment outcomes.
    Journal • CAR T-Cell Therapy • IO biomarker
    |
    IL10 (Interleukin 10)
    |
    CD33 CAR-T
    11ms
    Myeloid leukemia-derived galectin-1 downregulates CAR expression to hinder cytotoxicity of CAR T cells. (PubMed, J Transl Med)
    The discovery of the role of galectin-1 in cell surface CAR down-regulation provides important insights for developing strategies to restore anti-tumor functions.
    Journal • CAR T-Cell Therapy
    |
    CD33 (CD33 Molecule) • LGALS1 (Galectin 1)
    |
    CD33 CAR-T
    almost2years
    Off-the-Shelf, Multiplexed-Engineered iPSC-Derived CD33 CAR-NK Cells for Treatment of Acute Myeloid Leukemia (ASH 2022)
    Immune cell therapy has become a cornerstone in cancer therapy. When administered in combination with daratumumab, QN-023a demonstrated superior ADCC compared to unmodified iPSC-derived NK cells against primary AML blasts from patients. Together, we have engineered iPSC-derived QN-023a NK cells as promising clinical drug candidates for treatment of AML.
    IO biomarker
    |
    CD33 (CD33 Molecule) • IL15 (Interleukin 15) • NKG2D (killer cell lectin like receptor K1)
    |
    Darzalex (daratumumab) • CD33 CAR-T • QN-023a
    over2years
    Evaluate the Safety and Efficacy of CD33 CAR-T in Patients With R/R AML (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Zhejiang University
    New P1 trial
    |
    CD33 (CD33 Molecule)
    |
    CD33 positive
    |
    CD33 CAR-T
    over2years
    Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With R/R AML (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Zhejiang University
    New P1 trial
    |
    CD33 (CD33 Molecule)
    |
    CD33 positive
    |
    CD33 CAR-T • CLL1+CD33 CAR-T